PP77 Safety, Effectiveness, And Cost Effectiveness Of Telemedicine In Neurological Diseases. (23rd December 2022)

• Record Type: Journal Article
• Authors: León-Salas, Beatriz; Linertová, Renata; González-Hernández, Yadira; Infante-Ventura, Diego; de Armas-Castellano, Aythami; Hernández-Yumar, Aránzazu; García-García, Javier; García-Hernández, Miguel; Toledo-Chávarri, Ana; Carmona-Rodríguez, Montserrat; del Mar Trujillo-Martín, María
• Is Part Of: International journal of technology assessment in health care. Volume 38(2022)Supplement 1
• Page Start: S65
• Page End: S65
• Publication Date: 2022-12-23
• Subjects: Medical technology -- Periodicals; Technology assessment -- Periodicals; 610.28
• DOI: 10.1017/S0266462322002070
• Languages: English
• ISSNs: 0266-4623

Abstract

Abstract : Introduction: Telemedicine has been introduced in health services, but uncertainties about the real value of this strategy in the management of neurological diseases remain. Methods: A systematic review was undertaken of available scientific literature on the safety, effectiveness, and cost effectiveness of telemedicine combined with in-person visits, compared with usual care, for the treatment and follow-up assessment of patients with neurological diseases. The overall effect size for each neurological disease was estimated using meta-analysis. An economic analysis was performed from the societal and Spanish healthcare system perspectives. Results: Two economic studies were included for cost effectiveness and 25 randomized controlled trails (n=8, 976 patients) were included for the effectiveness and safety assessment (11 on cerebrovascular diseases, four on Parkinson's disease, three on multiple sclerosis, two on epilepsy, and one each on brain damage, dementia, spina bifida, migraine, and cerebral palsy). The types of telemedicine evaluated included: virtual visits (11 studies); telerehabilitation (seven studies); telephone calls (three studies); smartphone apps (two studies); and online software for computers (two studies). Subgroup analysis by type of telemedicine indicated no discernible effect for telemedicine combined with in-person visits on most of the outcomes analyzed for the various neurological diseases. Given the heterogeneity of diseases, types of telemedicine, and the results observed, a cost-minimization analysis was conducted. Combining telemedicine with in-person visits would cost EUR 2.55 per patient from the perspective of the healthcare system, but it would result in cost savings (EUR 27.34 per patient) from the societal perspective. Conclusions: The safety and effectiveness of combining in-person visits with telemedicine was similar to that of usual care, but it could be a cost-saving strategy in Spain from a societal perspective.